SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca
  • Francesca Pavanello
    Istituto Oncologico della Svizzera Italiana, Ospedale San Giovanni 6500 Bellinzona, Switzerland,
  • Sara Steffanoni
    Istituto Oncologico della Svizzera Italiana, Ospedale San Giovanni 6500 Bellinzona, Switzerland, | Sara.Steffanoni@eoc.ch
  • Michele Ghielmini
    Istituto Oncologico della Svizzera Italiana, Ospedale San Giovanni 6500 Bellinzona, Switzerland,
  • Emanuele Zucca
    Istituto Oncologico della Svizzera Italiana, Ospedale San Giovanni 6500 Bellinzona, Switzerland,

Abstract

The natural history of follicular lymphoma is usually characterized by an indolent course with a high response rate to the first line therapy followed by recurrent relapses, with a time to next treatment becoming shorter after each subsequent treatment line. More than 80% of patients have advanced stage disease at diagnosis. The time of initiation and the nature of the treatment is mainly conditioned by symptoms, tumor burden, lymphoma grading, co-morbidities and patients preference. A number of clinical and biological factors have been determined to be prognostic in this disease, but the majority of them could not show to be predictive of response to treatment, and therefore can’t be used to guide the treatment choice. CD20 expression is the only predictive factor recognized in the treatment of FL and justifies the use of “naked” or “conjugated” anti-CD20 monoclonal antibodies as single agent or in combination with chemo- or targeted therapy. Nevertheless, as this marker is almost universally found in FL, it has little role for the choice of treatment. The outcome of patients with FL improved significantly in the last years, mainly due to the widespread use of rituximab, autologous and allogeneic transplantation in young and fit relapsed patients, the introduction of new drugs and the improvement in diagnostic accuracy and management of side effects. Agents as new monoclonal antibodies, immuno-modulating drugs and target therapy have recently been developed and approved for the relapsed setting, while studies to evaluate their role in first line treatment are still ongoing. Here we report our considerations on first line treatment approach and on the potential factors which could help in the choice of therapy.


 

Keywords

Follicular Lymphoma, Therapy, CD 20 expression,

Full Text:

PDF
HTML
Submitted: 2016-10-21 19:04:40
Published: 2016-11-06 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
806

Views:
PDF
290
HTML
1038

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185